Pulmonary alveolar proteinosis – current and future therapeu... : Current Opinion in Pulmonary
Medicine Pulmonary alveolar proteinosis – current and future therapeutical strategies : Current …

Simple Summary Recently, cancer prognoses have improved by using a new class of drugs
called immune checkpoint inhibitors. These treatments work by helping a person's immune …

We describe a human lung disease caused by autosomal recessive, complete deficiency of
the monocyte chemokine receptor CC motif chemokine receptor 2 (CCR2). Nine children …

Rationale Whole lung lavage (WLL) is a widely accepted palliative treatment for
autoimmune pulmonary alveolar proteinosis (aPAP) but does not correct myeloid cell …

JAK-STAT cytokines are critical in regulating immunity. Persistent activation of JAK-STAT
signaling pathways by cytokines drives chronic inflammatory diseases such as asthma …

Background Pulmonary alveolar proteinosis (PAP) is a rare syndrome caused by several
distinct diseases leading to progressive dyspnoea, hypoxaemia, risk of respiratory failure …

Background: Autoimmune pulmonary alveolar proteinosis (aPAP) results from impaired
macrophage-mediated clearance of alveolar surfactant lipoproteins. Whole lung lavage has …

A growing body of evidence underscores the relevance of functional autoantibodies in the
development of various pathogenic conditions but also in the regulation of homeostasis …

Pulmonary fibrosis (PF) can be idiopathic or driven by a specific insult, genetic susceptibility,
or disease process. Inflammation plays a role in the pathophysiology, the extent of which …

Extract Autoimmune pulmonary alveolar proteinosis (aPAP) is associated with
autoantibodies against granulocyte–macrophage colony-stimulating factor (GM-CSF) in …